The potential for using real-world data (RWD) to support the development of cancer drugs for children has yet to be realized as researchers, sponsors and regulators continue to struggle with the collection of meaningful data.
Business development among biopharmaceutical companies working on therapeutics for cancer indications has been brisk this year, with 32% of the 654 deals recorded to date by BioWorld involving cancer indications. However public companies in the area haven’t gained much investor enthusiasm, with the BioWorld Cancer index dropping over 18% year-to-date, with 6% of the loss in valuation taking place this month.
While acknowledging the net health benefit over standard of care in heavily pretreated multiple myeloma patients, CAR T-cell therapies Abecma (idecabtagene vicleucel) and ciltacabtagene autoleucel (cilta-cel) represent low long-term value at their current pricing levels, according to the Institute for Clinical and Economic Review (ICER) in a final evidence report released May 11.
Appia Bio Inc. raised $52 million in a series A funding round to bring forward a novel take on allogeneic cell therapy for cancer, based on a rare lymphocyte population, invariant natural killer T (iNKT) cells, which exhibit aspects of both NK cell and T-cell biology.
Despite the demonstrated benefits of using patient-reported outcomes (PROs) in clinical trials assessing new cancer drugs in adults, PROs are rarely used in pediatric cancer trials. Hoping to change that, the FDA is convening the pediatric subcommittee of its Oncologic Drugs Advisory Committee (ODAC) May 11 to discuss how to effectively use a pediatric form of the PRO version of the common terminology criteria for adverse events.
Beigene Ltd.’s PARP inhibitor, pamiparib, won conditional approval from China’s National Medical Products Administration for treating patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.
Sporos Bioventures LLC closed a $38.1 million series A financing to develop a pipeline of therapies for treating cancer and immune diseases through four companies with a business structure that its chief financial officer, Michael Wyzga, described as a hub-and-spoke model that leans on diversification.
PERTH, Australia – Imagion Biosystems Ltd. has entered a collaborative research program with therapeutic antibody development company Patrys Ltd. to combine their technologies to target brain tumor imaging and diagnosis.
Eikon Therapeutics Inc., a startup leveraging advanced optics and machine learning to track protein dynamics for drug discovery, has closed a $148 million series A financing. Led by a high-profile CEO, former Merck & Co. Inc. R&D chief Roger Perlmutter, and with the counsel of two Nobel prize winners, its team is working to "expand the druggable proteome by targeting protein dynamics directly."
RSS
